Citations

Mayo Clinic

Showing 10 of 108523 citations.

Off-Label Use of Inhaled Nitric Oxide After Release of NIH Consensus Statement
Ellsworth, Marc A., Harris, Malinda N. , Carey, William A., Spitzer, Alan R., Clark, Reese H.

Pediatrics | March 10, 2015 | Volume: 135 | Issue: 4 | Pages: 643-648

10.1542/peds.2014-3290 | PMID 25755237 Get It

BACKGROUND:Inhaled nitric oxide (iNO) therapy is an off-label medication in infants <34 weeks’ gestational age. In 2011, the National Institutes of Health released a statement discouraging routine iNO use in premature infants. The objective of this study was to describe utilization patterns of iNO in American NICUs in the years surrounding the release of the National Institutes of Health statement. We hypothesized that iNO prescription rates in premature infants have remained unchanged since 2011.METHODS:The Pediatrix Medical Group Clinical Data Warehouse was queried for the years 2009–2013 to describe first exposure iNO use among all admitted neonates stratified by gestational age.RESULTS:Between 2009 and 2013, the rate of iNO utilization in 23- to 29-week neonates increased from 5.03% to 6.19%, a relative increase of 23% (confidence interval: 8%–40%; P = .003). Of all neonates who received iNO therapy in 2013, nearly half were <34 weeks’ gestation, with these infants accounting for more than half of all first exposure iNO days each year of the study period.CONCLUSIONS:The rates of off-label iNO use in preterm infants continue to rise despite evidence revealing no clear benefit in this population. This pattern of iNO prescription is not benign and comes with economic consequences.
Advances in Retinal Therapeutics
Carvounis, Petros , Albini, Thomas A. , Tsilimbaris, Miltiadis K. , Barkmeier, Andrew J. , Tsilimbaris, Miltiadis

Journal of Ophthalmology | March 9, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-1

10.1155/2015/515193 | PMID 25838940 Get It

Shared Decision Making and Use of Decision Aids for Localized Prostate Cancer
Wang, Elyn H. , Gross, Cary P. , Tilburt, Jon C. , Yu, James B. , Nguyen, Paul L. , Smaldone, Marc C., Shah, Nilay D. , Abouassally, Robert, Sun, Maxine , Kim, Simon P. , Yu, James B

JAMA Internal Medicine | March 9, 2015 | Volume: 175 | Issue: 5 | Pages: 792

10.1001/jamainternmed.2015.63 | PMID 25751604 Get It

Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T
Dispenzieri, Angela , Saenger, Amy K., Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Leung, Nelson , Zeldenrust, Steven R., Hayman, Suzanne R. , Kapoor, Prashant , Grogan, Martha , Hwa, Yi L. , Russell, Stephen J. , Kyle, Robert A. , Jaffe, Allan S. , Saenger, Amy, Buadi, Francis K. , Zeldenrust, Steven, Hwa, Lisa, Jaffe, Allan, Gertz, Morie A. , Go, Ronald S. , Rajkumar, S. Vincent , Jaffe, Allan S. , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

American Journal of Hematology | March 9, 2015 | Volume: 90 | Issue: 6 | Pages: 524-528

10.1002/ajh.24001 | PMID 25753178 Get It

The use of soluble cardiac biomarkers such as N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) and troponin has revolutionized prognostication for patients with AL amyloidosis. Soluble ST2 (sST2) and galectin‐3 have also been reported to have prognostic value in other cardiac patient populations. We identified 502 patients with AL amyloidosis, who provided a research sample and consent to review their medical records between 1/1/2006‐12/31/2010 within 90 days of their diagnosis. Samples were assayed for sST2 and galectin‐3. Within this AL amyloidosis population, overall survival (OS) was 25.5 months (95% CI 18, 35.7 months). Receiver operating curve analyses were done to detect the best cut‐points for sST2 and galectin‐3 to predict both 1‐ and 5‐year OS. The respective cut points for sST2 were 30 and 29.7 ng/mL, while the median sST2 for the entire population was 31 ng/mL (IQR 19.8, 53.6). The respective cut points for galectin‐3 were 11 and 10.4 ng/mL while the median for the entire population was 16.6 ng/mL (IQR 11.5, 24.0). Although on univariate analysis, both sST2 and galectin‐3 were prognostic, upon multivariate analysis, only sST2 was independent of troponin, NT‐proBNP, serum immunoglobulin free light chain, and blood pressure. Not only did sST2 add to previously reported prognostication systems, but a novel prognostication 5‐point system including sST2 was possible. The addition of sST2 – but not galectin‐3 – to existing prognostication systems for patients with AL amyloidosis strengthens the ability to predict for death. Am. J. Hematol. 90:524–528, 2015. © 2015 Wiley Periodicals, Inc.
Association of UCP‐3 rs1626521 with obesity and stomach functions in humans
Camilleri, Michael , Shin, Andrea , Vázquez‐Roque, María I. , Iturrino, Johanna , Lanza, Ian R. , Burton, Duane D. , O’Neill, Jessica, Eckert, Deborah J., Carlson, Paula, Zinsmeister, Alan R., Acosta, Andrés , Nair, K. Sreekumaran , Vella, Adrian , Lanza, Ian R

Obesity | March 7, 2015 | Volume: 23 | Issue: 4 | Pages: 898-906

10.1002/oby.21039 | PMID 25755013 Get It

ObjectiveTo examine the association of gene variants of uncoupling proteins (UCP)‐2 and −3 with obesity and gastrointestinal (GI) traits.MethodsIn 255 overweight or obese adults, the associations of gene variants in UCP‐2 (−3474, rs659366) and UCP‐3 (rs1626521, rs2075577, rs15763) with body weight (BW) and GI traits were studied. Gene variants were genotyped by TaqMan® assay. The associations of genotypes with BW and GI traits (gastric emptying, gastric volume, satiety by buffet meal, satiation by nutrient drink test and GI hormones) were assessed using ANOVA corrected for false detection rate (FDR).ResultsA novel UCP‐3 gene variant, rs1626521, was identified; it was associated with BW (P = 0.039), waist circumference (P = 0.035), and significantly higher postprandial gastric volume (P = 0.003) and calories ingested at buffet meal (P = 0.006, both significant with FDR). In a subgroup of 11 participants, rs1626521 was also associated with reduced mitochondrial bioenergetics efficiency in skeletal muscle (P = 0.051). In an in vitro study in HEK293 cells, rs1626521 reduced UCP‐3 protein expression (P = 0.049). Associations detected between other genotypes and GI traits were nonsignificant with FDR.ConclusionsA newly identified functional variant (rs1626521) in UCP‐3 affects postprandial gastric functions and satiety and may contribute to weight gain and alter human mitochondrial function.
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Kuiatse, Isere, Lin, Heather , Bjorklund, Chad C. , Weber, Donna M., Wang, Michael , Shah, Jatin J., Jones, Richard J., Ansell, Stephen M. , Orlowski, Robert Z. , Baladandayuthapani, Veerabhadran , Thomas, Sheeba K. , Zhang, Xing‐Ding , Yang, Guang , Treon, Steven P. , Orlowski, Robert Z.

Clinical Cancer Research | March 6, 2015 | Volume: 21 | Issue: 11 | Pages: 2538-2545

10.1158/1078-0432.ccr-14-1462 | PMID 25748087 Get It

Abstract Purpose: Waldenström macroglobulinemia (WMG) is a lymphoproliferative disorder characterized by good initial responses to standard therapeutics, but only a minority of patients achieve complete remissions, and most inevitably relapse, indicating a need for novel agents. B-cell receptor signaling has been linked to clonal evolution in WMG, and Spleen tyrosine kinase (Syk) is overexpressed in primary cells, suggesting that it could be a novel and rational target. Experimental Design: We studied the impact of the Syk inhibitor fostamatinib on BCWM.1 and MWCL-1 WMG-derived cell lines both in vitro and in vivo, as well as on primary patient cells. Results: In WMG-derived cell lines, fostamatinib induced a time- and dose-dependent reduction in viability, associated with activation of apoptosis. At the molecular level, fostamatinib reduced activation of Syk and Bruton's tyrosine kinase, and also downstream signaling through MAPK kinase (MEK), p44/42 MAPK, and protein kinase B/Akt. As a single agent, fostamatinib induced tumor growth delay in an in vivo model of WMG, and reduced viability of primary WMG cells, along with inhibition of p44/42 MAPK signaling. Finally, fostamatinib in combination with other agents, including dexamethasone, bortezomib, and rituximab, showed enhanced activity. Conclusions: Taken together, these data support the translation of approaches targeting Syk with fostamatinib to the clinic for patients with relapsed and possibly even newly diagnosed WMG. Clin Cancer Res; 21(11); 2538–45. ©2015 AACR.
Application of exercise transcutaneous oxygen pressure measurements for detection of proximal lower extremity arterial disease: A case report
Kalra, Manju , Abraham, Pierre , Liedl, David , Wennberg, Paul W. , Mahe, Guillaume, Liedl, David A, Mahé, Guillaume

Vascular Medicine | March 6, 2015 | Volume: 20 | Issue: 3 | Pages: 251-255

10.1177/1358863x14567030 | PMID 25750011 Get It

Proximal claudication is secondary to ischemia caused by peripheral artery disease (PAD), whereas proximal pseudo-claudication is secondary to other disease processes such as hip arthritis, spinal stenosis, neuropathy, and so forth. The differentiation between the two can be challenging. Exercise transcutaneous oxygen pressure measurement (exercise-TcPO 2 ) allows noninvasive detection of flow-reducing lesions in the proximal arteries and tributaries of the lower extremity arterial tree. We present the first case report in the United States using an exercise-TcPO 2 algorithm. A 71-year-old diabetic patient with proximal left-sided and right-calf claudication with indeterminate ankle-brachial indices underwent an exercise-TcPO 2 study before and after endovascular intervention. Four TcPO 2 probes were placed: one at chest level (reference probe), one on each buttock, and one on the symptomatic calf. The Delta from Resting Oxygen Pressure (DROP) index was calculated at each probe site using a previously validated protocol. Proximal left- and right-calf ischemia were confirmed by the initial exercise-TcPO 2 , and, after endovascular treatment of the left iliac artery lesion, improvements in proximal exercise-TcPO 2 values were found. These data suggest that exercise-TcPO 2 can be useful in PAD evaluation in patients with non-compressible arteries and/or proximal claudication.
Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma
Wreesmann, Volkert B. , Nixon, Iain J. , Rivera, Michael , Katabi, Nora , Palmer, Frank L., Ganly, Ian , Shaha, Ashok R. , Tuttle, R. Michael , Shah, Jatin P. , Patel, Snehal G. , Ghossein, Ronald

Thyroid® | March 6, 2015 | Volume: 25 | Issue: 5 | Pages: 503-508

10.1089/thy.2015.0052 | PMID 25748079 Get It

Background: Vascular invasion (VI) is an important predictor of distant metastasis and possible radioactive iodine (RAI) benefit in follicular, Hürthle cell, and poorly differentiated thyroid carcinomas, but its role in well-differentiated papillary thyroid cancer (WDTC) remains unclear. Methods: Archived pathological material of all differentiated thyroid carcinoma patients undergoing primary surgical treatment at Memorial Sloan-Kettering Cancer Center between 1986 and 2003 was reviewed by two dedicated thyroid pathologists. Only WDTCs were included in the present study. Standard statistical methods were used to assess the relationship between VI and outcomes of interest, including 10-year disease-specific survival (DSS), regional recurrence-free survival (RRFS), and distant recurrence-free survival (DRFS). Results: VI was present in 47 of 698 WDTC (6.7%). VI was significantly associated with tumor size >4.0 cm, extrathyroidal extension, distant metastasis, and RAI treatment. On univariate analysis, VI was predictive of decreased 10-year DRFS, but not DSS or RRFS. On multivariate analysis, VI was not an independent predictor of DRFS. Univariate survival analysis of 422 RAI-naïve WDTC showed that both size >4 cm and VI were predictors of outcome, but only size remained independently predictive on multivariate analysis. Conclusion: The presence of VI is not an independent predictor of outcome in WDTC.
Faculty Opinions recommendation of Where should I send it? Optimizing the submission decision process.
Kashani, Kianoush

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 6, 2015 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725324668.793504586 Get It